DIHYDROFOLATE REDUCTASE AND DIHYDROPTERO
WITH IN VITRO RESISTANCE OF PLASMODIUM FALCI
SULFADOXINE, AND SULFAMETHOXAZOLE

American Journal of Tropical Medicine and Hygiene

68, 586-589

DOI: 10.4269/ajtmh.2003.68.586

Citation Report

#	Article	IF	Citations
1	Drug Susceptibility and Genetic Evaluation of Plasmodium falciparum Isolates Obtained in Four Distinct Geographical Regions of Kenya. Antimicrobial Agents and Chemotherapy, 2004, 48, 3598-3601.	1.4	24
2	Editorial: Antifolates in prevention of HIV-associated opportunistic infections and in intermittent preventive treatment of malaria in Africa. Tropical Medicine and International Health, 2005, 10, 293-294.	1.0	3
3	Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Tropical Medicine and International Health, 2005, 10, 901-908.	1.0	63
4	Mechanisms of Resistance of Malaria Parasites to Antifolates. Pharmacological Reviews, 2005, 57, 117-145.	7.1	400
5	High Prevalence of Markers for Sulfadoxine and Pyrimethamine Resistance in Plasmodium falciparum in the Absence of Drug Pressure in the Ashanti Region of Ghana. Antimicrobial Agents and Chemotherapy, 2005, 49, 1101-1105.	1.4	44
6	DNA and RNA Synthesis:â€‰ Antifolates. Chemical Reviews, 2005, 105, 593-620.	23.0	210
7	Raising Antibodies in Chickens Against Primaquine, Pyrimethamine, Dapsone, Tetracycline, and Doxycycline. Immunological Investigations, 2005, 34, 101-114.	1.0	5
8	Drug resistance to sulphadoxine-pyrimethamine in Plasmodium falciparum malaria in Mlimba, Tanzania. Malaria Journal, 2006, 5, 94.	0.8	27
9	Antifolate Resistance inPlasmodium falciparum:Multiple Origins and Identification of NoveldhfrAlleles. Journal of Infectious Diseases, 2006, 194, 189-197.	1.9	122
10	Genetic characterization of the dihydrofolate reductase gene of Pneumocystis jirovecii isolates from Portugal. Journal of Antimicrobial Chemotherapy, 2006, 58, 1246-1249.	1.3	22
11	Common Origin and Fixation of Plasmodium falciparum dhfr and dhps Mutations Associated with Sulfadoxine-Pyrimethamine Resistance in a Low-Transmission Area in South America. Antimicrobial Agents and Chemotherapy, 2007, 51, 2085-2091.	1.4	111
12	Prevalence of mutations associated with antimalarial drugs in Plasmodium falciparum isolates prior to the introduction of sulphadoxine-pyrimethamine as first-line treatment in Iran. Malaria Journal, 2007, 6, 148.	0.8	16
13	Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique. Malaria Journal, 2008, 7, 115.	0.8	29
14	The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malaria Journal, 2008, 7, 61.	0.8	24
15	Aquatic Plants Exposed to Pharmaceuticals: Effects and Risks. Reviews of Environmental Contamination and Toxicology, 2008, 192, 67-115.	0.7	116
16	Emergence of adhfrMutation Conferring Highâ€Level Drug Resistance inPlasmodium falciparumPopulations from Southwest Uganda. Journal of Infectious Diseases, 2008, 197, 1598-1604.	1.9	76
17	Prophylaxis and treatment of malaria in HIV-infected populations. Future HIV Therapy, 2008, 2, 453-464.	0.5	3
18	In Vitro Activity of Antifolate and Polymorphism in Dihydrofolate Reductase ofPlasmodium falciparumIsolates from the Kenyan Coast: Emergence of Parasites with Ile-164-Leu Mutation. Antimicrobial Agents and Chemotherapy, 2009, 53, 3793-3798.	1.4	46

#	Article	IF	Citations
19	Emergence of an Unusual Sulfadoxineâ€Pyrimethamine Resistance Pattern and a Novel K540N Mutation in Dihydropteroate Synthetase inPlasmodium falciparumIsolates Obtained from Car Nicobar Island, India, after the 2004 Tsunami. Journal of Infectious Diseases, 2009, 199, 1064-1073.	1.9	28
20	Targets, Effects and Risks in Aquatic Plants Exposed to Veterinary Antibiotics. ACS Symposium Series, 2010, , 169-189.	0.5	10
21	Anti-folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malaria Journal, 2010, 9, 247.	0.8	95
22	Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malaria Journal, 2010, 9, 338.	0.8	45
23	Analysis of the dihydrofolate reductase-thymidylate synthase gene sequences in Plasmodium vivax field isolates that failed chloroquine treatment. Malaria Journal, 2010, 9, 331.	0.8	9
24	HIV-Associated Pneumocystis Pneumonia. Proceedings of the American Thoracic Society, 2011, 8, 294-300.	3.5	146
25	Haplotypes associated with resistance to sulfadoxineâ€“pyrimethamine in Plasmodium falciparum in two malaria endemic locations in Colombia. Infection, Genetics and Evolution, 2013, 18, 183-190.	1.0	4
26	Effectiveness of two antifolate prophylactic strategies against malaria in HIV-positive pregnant women in Bangui, Central African Republic: study protocol for a randomized controlled trial (MACOMBA). Trials, 2013, 14, 255.	0.7	2
27	Trends in drug resistance codons in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase genes in Kenyan parasites from 2008 to 2012. Malaria Journal, 2014, 13, 250.	0.8	21
28	Molecular Analysis of Chloroquine and Sulfadoxine-Pyrimethamine Resistance-Associated Alleles in Plasmodium falciparum Isolates from Nicaragua. American Journal of Tropical Medicine and Hygiene, 2014, 90, 840-845.	0.6	10
29	Sulfonamide inhibition study of the carbonic anhydrases from the bacterial pathogen Porphyromonas gingivalis: The Î²-class (PgiCAb) versus the Î³-class (PgiCA) enzymes. Bioorganic and Medicinal Chemistry, 2014, 22, 4537-4543.	1.4	34
30	Sulfa and trimethoprim-like drugs â€“ antimetabolites acting as carbonic anhydrase, dihydropteroate synthase and dihydrofolate reductase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2014, 29, 379-387.	2.5	255
31	High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Malaria Journal, 2015, 14, 439.	0.8	30
32	Use of bacterial surrogates as a tool to explore antimalarial drug interaction: Synergism between inhibitors of malarial dihydrofolate reductase and dihydropteroate synthase. Acta Tropica, 2015, 149, 64-69.	0.9	2
33	Molecular surveillance of Plasmodium falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Acta Tropica, 2016, 164, 329-336.	0.9	30
34	<scp>MRP</scp>1 mediates folate transport and antifolate sensitivity in Plasmodium falciparum. FEBS Letters, 2016, 590, 482-492.	1.3	13
35	Lausannevirus Encodes a Functional Dihydrofolate Reductase Susceptible to Proguanil. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	0
36	Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort. Infection, 2017, 45, 341-347.	2.3	19

#	Article	IF	Citations
37	Simple detection of single nucleotide polymorphism in Plasmodium falciparum by SNP-LAMP assay combined with lateral flow dipstick. Parasitology International, 2017, 66, 964-971.	0.6	49
39	Increased Frequency of Pfdhps A581G Mutation in Plasmodium falciparum Isolates from Gabonese HIV-Infected Individuals. Malaria Research and Treatment, 2019, 2019, 1-8.	2.0	2
40	Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes. Acta Tropica, 2020, 212, 105704.	0.9	4
41	High multiple mutations of Plasmodium falciparum-resistant genotypes to sulphadoxine-pyrimethamine in Lagos, Nigeria. Infectious Diseases of Poverty, 2020, 9, 91.	1.5	27
42	Changes in the frequencies of Plasmodium falciparum dhps and dhfr drug-resistant mutations in children from Western Kenya from 2005 to 2018: the rise of Pfdhps S436H. Malaria Journal, 2020, 19, 378.	0.8	14
43	A novel sulfamethoxazole derivative as an inhibitory agent against HSP70: A combination of computational with in vitro studies. International Journal of Biological Macromolecules, 2021, 189, 194-205.	3.6	7
44	Declining trend of Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant alleles after the withdrawal of Sulfadoxine-Pyrimethamine in North Western Ethiopia. PLoS ONE, 2015, 10, e0126943.	1.1	16
45	COMPARISON OF THE PARASITOLOGIC EFFICACY OF AMODIAQUINE AND SULFADOXINE-PYRIMETHAMINE IN THE TREATMENT OF PLASMODIUM FALCIPARUM MALARIA IN THE BUNGOMA DISTRICT OF WESTERN KENYA. American Journal of Tropical Medicine and Hygiene, 2004, 71, 537-541.	0.6	9
46	PRINCIPAL ROLE OF DIHYDROPTEROATE SYNTHASE MUTATIONS IN MEDIATING RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN SINGLE-DRUG AND COMBINATION THERAPY OF UNCOMPLICATED MALARIA IN UGANDA. American Journal of Tropical Medicine and Hygiene, 2004, 71, 758-763.	0.6	47
47	POLYMORPHISMS IN PFCRT, PFMDR1, DHFR GENES AND IN VITRO RESPONSES TO ANTIMALARIALS IN PLASMODIUM FALCIPARUM ISOLATES FROM BANGUI, CENTRAL AFRICAN REPUBLIC. American Journal of Tropical Medicine and Hygiene, 2006, 75, 381-387.	0.6	28
48	High Prevalence and Fixation of Plasmodium vivax dhfr/dhps Mutations Related to Sulfadoxine/Pyrimethamine Resistance in French Guiana. American Journal of Tropical Medicine and Hygiene, 2009, 81, 19-22.	0.6	16
50	Drug-resistant malaria in Sudan: A review of evidence and scenarios for the future. Sudanese Journal of Paediatrics, 2012, 12, 8-20.	0.6	7